Navigation Links
Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
Date:12/8/2011

eutical company developing novel oncology compounds that target cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinically active compounds, both of which have demonstrated durable complete responses (CRs) and an overall survival (OS) benefit in Phase I/II studies. SL-401 has completed a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) where it has demonstrated single agent activity, including two durable CRs and an OS benefit, in heavily pretreated patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. SL-401 is also currently being tested in additional indications including chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). The Company's second clinical program, SL-701, has demonstrated single agent activity including durable tumor responses, which includes CRs, multiple partial responses (PRs) and an OS benefit, in Phase I/II trials of adult patients with refractory or recurrent high grade glioma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.

Stemline Contact:
Mark Jacobson
Associate Director, Business Development
Stemline Therapeutics, Inc.
Tel: 212-584-5747
Email: mjacobson@stemline.com

This announcement contains forward-looking statements relating to Stemline's business, which are based on the Company's current expectations concerning future d
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
2. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
3. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
6. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
7. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
8. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
9. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
10. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
11. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that executives from the company will ... September.  , Pedro Lichtinger , ... 17th Annual Global Investment Conference on Wednesday, September 10, ... Hotel in New York City . ...
(Date:8/27/2015)... HUYA Bioscience International (HUYA) today announced the sponsorship ... of HTLV-1, held this week at the University of ... Society is to promote research on HTLV-1 and HTLV-1-associated ... and research related to these fields to advance science, ... proud to support this prestigious conference," said Mireille ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
(Date:8/27/2015)... TRIANGLE PARK, N.C. , Aug. 27, 2015 ... on the decision by FedEx, UPS and The ... of certain biological specimens classified as ,select agents, ... and long history of handling these sensitive shipments. ... knowledge of global transportation regulations, trained and certified ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... energy could be a central alternative to petroleum-based energy ... the same energy yield and is more expensive to ... solar energy production on the environment is incomplete, experts ... benefits and detriments of solar power, a research team ...
... Mass.With the potential to save tens of thousands of ... by MassBiologics at the University of Massachusetts and the ... with positive results from a Phase 1 study. The ... (RAB-1) resulted in protective antibody levels in the serum ...
... 16 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: ... Annual Meeting of Shareholders (the "Annual Meeting") held on ... Meeting, shareholders elected John H. Bauer and Phillip M. ... Directors until the Company,s 2013 Annual Meeting. Shareholders approved ...
Cached Biology Technology:Research team assesses environmental impact of organic solar cells 2New treatment for rabies advances after successful phase 1 trial in India 2New treatment for rabies advances after successful phase 1 trial in India 3Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders 2
(Date:8/4/2015)... Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today reported ... 2015. Highlights: , Second quarter contract revenue ... 2014 , Adjusted contract margins of ... $0.22, including a $0.05 decrease in EPS from royalties in the ... million "We are very pleased to present another ...
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... TAMPA, Fla. Dec. 18, 2012 Four ... been named charter fellows to the National Academy ... chair of the Bioengineering Department; Nai Yuen Chen, ... research professor in the Materials Science and Engineering ...
... Neurodegenerative Diseases (DZNE) and the University of Bonn are ... composed of several proteins and plays a key role ... sensor that triggers a chain reaction when activated. As ... foster inflammation are released. This process can be triggered ...
... decorating mantles to the new outfits in display windows calling ... holiday season. For bioenergy researchers, however, fiber composition matters more ... of more than two dozen coils of cellulose, a target ... edition of Nature , an international consortium of researchers ...
Cached Biology News:National Academy of Inventors names four UT Arlington professors as charter fellows 2Alzheimer's disease: Cutting off immune response promises new approach to therapy 2Unraveling the threads: Simplest cotton genome offers clues for fiber improvements 2Unraveling the threads: Simplest cotton genome offers clues for fiber improvements 3
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... powerful application for DNA and protein ... Expression makes complex computational analyses of ... the very latest computing technology to ... sequences are analysed. Features include: Sequence ...
... TYPE II Reacts with most of ... cell keratin of 86 and 58kD and ... keratin reactivity is found on human epidermal ... Immunogen: Human epidermal cells ...
Biology Products: